Fluocinolone Acetonide
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Fluocinolone Acetonide: Lichen planus pemphigoides
One-Sentence Summary
Fluocinolone acetonide is a synthetic topical corticosteroid used for inflammatory and itchy skin conditions. The TxGNN model predicts it may be useful for lichen planus pemphigoides, but no clinical trials and no publications were found to support this direction, so it remains a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Lichen planus pemphigoides |
| TxGNN Prediction Score | 0.9934 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Pharmacology data show that fluocinolone acetonide acts on the glucocorticoid receptor (NR3C1), the target through which corticosteroids exert anti-inflammatory and anti-itch effects in the skin.
Lichen planus pemphigoides is a rare overlap of lichen planus and bullous pemphigoid, with autoantibodies against BP180 (collagen XVII). Topical corticosteroids are used for localized disease, so the anti-inflammatory action of fluocinolone acetonide gives a limited, plausible rationale for mild or localized disease. Moderate to severe cases usually need systemic corticosteroids or other immunosuppressants, and a topical agent is unlikely to be sufficient on its own.
The prediction score (0.9934) is a model output without clinical support and should not be read as proof of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Marketed products containing fluocinolone acetonide as a single ingredient include the following. At least 20 valid licences were found, and this list may be partial.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 217232 | Three Derm Cream | Cream, tube of 5 gm | Not stated in the records |
| 86160 | Fluocin-MF Cream | Cream, tube of 15 gm | Not stated in the records |
| 43834 | Candi Cream | Cream, tube of 15 gm | Not stated in the records |
| 59932 | Dermolam Cream | Cream, tube of 15 gm | Not stated in the records |
| 231826 | Ultiderm CS Ointment | Ointment, tube of 50 gm | Not stated in the records |
Safety Considerations
- Contraindications (disease-level relations in the data compiled for this report, not label text): sunburn, herpes simplex infections (including herpes simplex keratitis), adrenocortical insufficiency/Addison disease, glaucoma, skin atrophy, telangiectasis and other capillary disease, peripheral vascular disease, herpes zoster, fungal eye infection, ocular tuberculosis, mycotic corneal ulcer.
- Drug Interactions: Ten interaction records were found, including dexamethasone, cetirizine, citalopram, valproic acid, acetaminophen, digoxin, levothyroxine, alendronic acid and clonazepam. Severity levels are not classified, so clinical significance is unknown.
Please also refer to the package insert for full warnings, as label-based warnings were not available.
Conclusion and Next Steps
Decision: Hold
Rationale: The only support is a model prediction (L5), with no trials or literature for lichen planus pemphigoides. A topical corticosteroid is plausible only for mild or localized disease.
To proceed, the following is needed:
- Case series, case reports or clinical studies of topical fluocinolone acetonide in lichen planus pemphigoides
- Package insert warnings and contraindications from the India regulatory source
- Mechanism-of-action data
- Assessment of which patients (localized versus moderate to severe disease) could realistically benefit from a topical product
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.